Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):198–204. doi: 10.1038/bjc.1998.464

Neoplastic progression of breast epithelial cells--a molecular analysis.

W Z Wei 1, R Pauley 1, D Lichlyter 1, H Soule 1, W P Shi 1, G Calaf 1, J Russo 1, R F Jones 1
PMCID: PMC2062906  PMID: 9683293

Abstract

Molecular changes associated with breast cancer progression were characterized using the MCF-10F cell series. MCF-10F was established from fibrous mastectomy tissue of a patient without detectable cancer. In vitro treatment of MCF-10F cells with benzo(a)pyrene resulted in a transformed subclone MCF-10F-BP1 (BP1). Transfection of clone BP1 with T24-Hras resulted in the tumorigenic line MCF-10F-BP1-Tras (BP1-Tras). Using flow cytometry, the expression of HLA I, ERBB-2 and MUC-1 was found to be comparable in 'normal' MCF-10F, transformed BP1 and tumorigenic BP1-Tras cells. Glycosylated mucin is elevated in BP1 but reduced in BP1-Tras cells. Using mRNA differential display analysis, cDNA profiles of the 'normal', transformed and tumorigenic cell lines were strikingly similar, yet distinct and elevated expression of several common cDNA fragments was detected in BP1 and BP1-Tras when compared with MCF-10F cells. These fragments were cloned and sequenced. The sequences of clones T1-360 and C4-310 are homologous to two reported EST cDNA clones from human fetal tissue and were further characterized. Elevated expression of the genes corresponding to clones T1-360 and C4-310 was verified using Northern blotting. High-level expression of these genes was also detected in the breast cancer cell line MCF-7 that was derived from the pleural effusion of a patient with advanced breast cancer. Therefore, specific molecular changes associated with breast cancer development were identified and may be indicators of neoplastic progression.

Full text

PDF
198

Images in this article

200Figure 3
on p.200
201Figure 4
on p.201

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bargmann C. I., Hung M. C., Weinberg R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986 Jan 16;319(6050):226–230. doi: 10.1038/319226a0. [DOI] [PubMed] [Google Scholar]
  2. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987 Oct 15;47(20):5476–5482. [PubMed] [Google Scholar]
  3. Calaf G., Russo J. Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis. 1993 Mar;14(3):483–492. doi: 10.1093/carcin/14.3.483. [DOI] [PubMed] [Google Scholar]
  4. Finn O. J., Jerome K. R., Henderson R. A., Pecher G., Domenech N., Magarian-Blander J., Barratt-Boyes S. M. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev. 1995 Jun;145:61–89. doi: 10.1111/j.1600-065x.1995.tb00077.x. [DOI] [PubMed] [Google Scholar]
  5. Girling A., Bartkova J., Burchell J., Gendler S., Gillett C., Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer. 1989 Jun 15;43(6):1072–1076. doi: 10.1002/ijc.2910430620. [DOI] [PubMed] [Google Scholar]
  6. Paine T. M., Soule H. D., Pauley R. J., Dawson P. J. Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer. 1992 Feb 1;50(3):463–473. doi: 10.1002/ijc.2910500323. [DOI] [PubMed] [Google Scholar]
  7. Pauley R. J., Soule H. D., Tait L., Miller F. R., Wolman S. R., Dawson P. J., Heppner G. H. The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. Eur J Cancer Prev. 1993 Nov;2 (Suppl 3):67–76. [PubMed] [Google Scholar]
  8. Pitot H. C., Dragan Y. P. Facts and theories concerning the mechanisms of carcinogenesis. FASEB J. 1991 Jun;5(9):2280–2286. [PubMed] [Google Scholar]
  9. Soule H. D., Maloney T. M., Wolman S. R., Peterson W. D., Jr, Brenz R., McGrath C. M., Russo J., Pauley R. J., Jones R. F., Brooks S. C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990 Sep 15;50(18):6075–6086. [PubMed] [Google Scholar]
  10. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  11. Toikkanen S., Helin H., Isola J., Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992 Jul;10(7):1044–1048. doi: 10.1200/JCO.1992.10.7.1044. [DOI] [PubMed] [Google Scholar]
  12. Wright C., Nicholson S., Angus B., Sainsbury J. R., Farndon J., Cairns J., Harris A. L., Horne C. H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992 Jan;65(1):118–121. doi: 10.1038/bjc.1992.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Xie Y., Pendergast A. M., Hung M. C. Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J Biol Chem. 1995 Dec 22;270(51):30717–30724. doi: 10.1074/jbc.270.51.30717. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES